• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腹腔内顺铂和阿霉素作为不可切除卵巢癌的维持化疗:病例报告

Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report.

作者信息

Tempfer Clemens B, Hartmann Franziska, Hilal Ziad, Rezniczek Günther A

机构信息

Department of Obstetrics and Gynecology, Ruhr University Bochum, Bochum, Germany.

Department of Pathology, Ruhr University Bochum, Bochum, Germany.

出版信息

BMC Cancer. 2017 Jan 6;17(1):26. doi: 10.1186/s12885-016-3004-8.

DOI:10.1186/s12885-016-3004-8
PMID:28061769
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5216537/
Abstract

BACKGROUND

Primary advanced, unresectable ovarian cancer (OC) is treated with palliative systemic chemotherapy. Intraperitoneal chemotherapy may be an alternative local maintenance therapy.

CASE PRESENTATION

A 75 year old woman with laparoscopically and histologically confirmed unresectable OC was treated with 13 cycles of intraperitoneal cisplatin 7.5 mg/m and doxorubicin 1.5 mg/m over 2 years using laparoscopic pressurized intraperitoneal aerosol chemotherapy (PIPAC). Objective tumor response (tumor regression on histology, stable disease on repeated video-laparoscopy and peritoneal carcinomatosis index) was noted. No Common Terminology Criteria for Adverse Events (CTCAE) > grade 3 were observed. EORTC QLQ-C30 quality of life measurements were stable throughout the therapy.

CONCLUSIONS

Repeated intraperitoneal chemotherapy with cisplatin and doxorubicin applied as PIPAC may be an effective maintenance treatment in women with primary advanced, unresectable OC.

摘要

背景

原发性晚期、无法切除的卵巢癌(OC)采用姑息性全身化疗进行治疗。腹腔内化疗可能是一种替代性的局部维持治疗方法。

病例报告

一名75岁女性,经腹腔镜检查及组织学确诊为无法切除的OC,在2年时间内接受了13个周期的腹腔镜加压腹腔内气溶胶化疗(PIPAC),使用顺铂7.5 mg/m²和阿霉素1.5 mg/m²进行腹腔内化疗。观察到客观肿瘤反应(组织学上肿瘤消退、重复视频腹腔镜检查时疾病稳定以及腹膜癌指数)。未观察到不良事件通用术语标准(CTCAE)>3级的情况。整个治疗过程中欧洲癌症研究与治疗组织QLQ-C30生活质量测量结果稳定。

结论

以PIPAC方式重复应用顺铂和阿霉素进行腹腔内化疗,对于原发性晚期、无法切除的OC女性患者可能是一种有效的维持治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5a4/5216537/a285b0a2933f/12885_2016_3004_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5a4/5216537/6de8eabaeefe/12885_2016_3004_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5a4/5216537/7327823a312c/12885_2016_3004_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5a4/5216537/adb86f22433a/12885_2016_3004_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5a4/5216537/a285b0a2933f/12885_2016_3004_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5a4/5216537/6de8eabaeefe/12885_2016_3004_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5a4/5216537/7327823a312c/12885_2016_3004_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5a4/5216537/adb86f22433a/12885_2016_3004_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5a4/5216537/a285b0a2933f/12885_2016_3004_Fig4_HTML.jpg

相似文献

1
Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report.腹腔内顺铂和阿霉素作为不可切除卵巢癌的维持化疗:病例报告
BMC Cancer. 2017 Jan 6;17(1):26. doi: 10.1186/s12885-016-3004-8.
2
Low-dose pressurized intraperitoneal aerosol chemotherapy (PIPAC) as an alternative therapy for ovarian cancer in an octogenarian patient.低剂量腹腔内加压气雾化疗(PIPAC)作为一名老年卵巢癌患者的替代治疗方法
Anticancer Res. 2015 Apr;35(4):2309-14.
3
Pressurized Intraperitoneal Aerosol Chemotherapy with Cisplatin and Doxorubicin in Women with Peritoneal Carcinomatosis: A Cohort Study.顺铂和阿霉素加压腹腔雾化化疗治疗腹膜癌病女性患者:一项队列研究
Anticancer Res. 2015 Dec;35(12):6723-9. doi: 10.1055/s-0035-1560004.
4
A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis.一项在复发性卵巢癌和腹膜癌病患者中进行的腹腔内顺铂和多柔比星的 I 期、单臂、开放标签、剂量递增研究。
Gynecol Oncol. 2018 Jul;150(1):23-30. doi: 10.1016/j.ygyno.2018.05.001. Epub 2018 May 6.
5
Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience.顺铂和多柔比星加压腹腔内化疗(PIPAC)治疗铂类耐药复发性卵巢癌女性患者的疗效:初步临床经验。
Gynecol Oncol. 2014 Feb;132(2):307-11. doi: 10.1016/j.ygyno.2013.11.022. Epub 2013 Nov 23.
6
Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study.复发性卵巢癌女性患者的腹腔内加压雾化化疗:一项2期研究。
Gynecol Oncol. 2015 May;137(2):223-8. doi: 10.1016/j.ygyno.2015.02.009. Epub 2015 Feb 18.
7
Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC).接受腹腔加压气溶胶化疗(PIPAC)治疗的终末期腹膜转移患者的生活质量
Eur J Surg Oncol. 2015 Oct;41(10):1379-85. doi: 10.1016/j.ejso.2015.06.001. Epub 2015 Jun 21.
8
Concentrations of cisplatin and doxorubicin in ascites and peritoneal tumor nodules before and after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal metastasis.腹腔内压力雾化化疗(PIPAC)前后腹腔转移患者腹水中顺铂和阿霉素浓度及腹膜肿瘤结节浓度。
Eur J Surg Oncol. 2018 Jul;44(7):1112-1117. doi: 10.1016/j.ejso.2018.04.020. Epub 2018 May 4.
9
Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis.腹腔内加压气雾化疗(PIPAC)联合全身化疗的安全性和可行性:一种治疗腹膜癌病的创新方法。
World J Surg Oncol. 2016 Apr 29;14:128. doi: 10.1186/s12957-016-0892-7.
10
No Renal Toxicity After Repeated Treatment with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Unresectable Peritoneal Metastasis.不可切除性腹膜转移患者经腹腔加压气雾剂化疗(PIPAC)重复治疗后无肾毒性。
Anticancer Res. 2018 Dec;38(12):6869-6875. doi: 10.21873/anticanres.13062.

引用本文的文献

1
Efficacy and safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in ovarian cancer: a systematic review of current evidence.腹腔内热灌注化疗(PIPAC)治疗卵巢癌的疗效和安全性:当前证据的系统评价。
Arch Gynecol Obstet. 2024 Oct;310(4):1845-1856. doi: 10.1007/s00404-024-07586-z. Epub 2024 Jun 15.
2
Pressurized intraperitoneal aerosol chemotherapy (PIPAC): updated systematic review using the IDEAL framework.腹腔内加压气雾化疗(PIPAC):使用IDEAL框架的最新系统评价
Br J Surg. 2022 Dec 13;110(1):10-18. doi: 10.1093/bjs/znac284.
3
Pressurized intraperitoneal aerosol chemotherapy for recurrent ovarian, fallopian or primary peritoneal cancer with peritoneal carcinomatosis: a narrative review.

本文引用的文献

1
High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.高水平的预处理CA125与高级别浆液性卵巢癌患者生存率的提高相关。
J Ovarian Res. 2016 Jul 7;9(1):41. doi: 10.1186/s13048-016-0247-6.
2
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis.低剂量顺铂和阿霉素的腹腔内加压气雾化疗(PIPAC)用于胃腹膜转移
J Gastrointest Surg. 2016 Feb;20(2):367-73. doi: 10.1007/s11605-015-2995-9. Epub 2015 Oct 28.
3
Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis.
腹腔内加压雾化化疗用于复发性卵巢癌、输卵管癌或原发性腹膜癌伴腹膜转移癌:一项叙述性综述
Gland Surg. 2021 Mar;10(3):1244-1251. doi: 10.21037/gs-2019-ursoc-12.
4
Identification of key genes for guiding chemotherapeutic management in ovarian cancer using translational bioinformatics.利用转化生物信息学鉴定指导卵巢癌化疗管理的关键基因
Oncol Lett. 2020 Aug;20(2):1345-1359. doi: 10.3892/ol.2020.11672. Epub 2020 May 22.
5
Pressurized intraperitoneal aerosol chemotherapy: a review of the introduction of a new surgical technology using the IDEAL framework.加压腹腔内气溶胶化疗:使用 IDEAL 框架引入新手术技术的回顾。
BJS Open. 2020 Apr;4(2):206-215. doi: 10.1002/bjs5.50257. Epub 2020 Jan 19.
6
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases of pancreas and biliary tract cancer.腹腔内高压气溶胶化疗(PIPAC)治疗胰腺和胆道癌的腹膜转移。
Clin Exp Metastasis. 2018 Oct;35(7):635-640. doi: 10.1007/s10585-018-9925-7. Epub 2018 Jul 30.
7
The scientific report from the first pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures performed in the eastern part of Central Europe.中欧东部首次进行的腹腔内加压气雾化疗(PIPAC)手术的科学报告。
J Int Med Res. 2018 Sep;46(9):3748-3758. doi: 10.1177/0300060518778637. Epub 2018 Jun 19.
奥沙利铂腹腔内加压雾化化疗用于结直肠癌腹膜转移
Colorectal Dis. 2016 Apr;18(4):364-71. doi: 10.1111/codi.13130.
4
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in a woman with pseudomyxoma peritonei: A case report.一名腹膜假黏液瘤女性患者接受顺铂和阿霉素的腹腔内加压气雾化疗(PIPAC):病例报告
Gynecol Oncol Rep. 2014 Oct 18;10:32-5. doi: 10.1016/j.gore.2014.10.001. eCollection 2014 Dec.
5
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.新诊断的晚期卵巢癌的初次化疗与初次手术(CHORUS):一项开放标签、随机、对照、非劣效性试验。
Lancet. 2015 Jul 18;386(9990):249-57. doi: 10.1016/S0140-6736(14)62223-6. Epub 2015 May 19.
6
Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study.复发性卵巢癌女性患者的腹腔内加压雾化化疗:一项2期研究。
Gynecol Oncol. 2015 May;137(2):223-8. doi: 10.1016/j.ygyno.2015.02.009. Epub 2015 Feb 18.
7
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.拓扑替康、聚乙二醇化脂质体盐酸多柔比星、紫杉醇、曲贝替定和吉西他滨用于晚期复发性或难治性卵巢癌:一项系统评价和经济学评估
Health Technol Assess. 2015 Jan;19(7):1-480. doi: 10.3310/hta19070.
8
A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer.一项奥沙利铂联合拓扑替康持续输注治疗既往治疗的卵巢癌患者的 II 期研究。
Int J Gynecol Cancer. 2013 Nov;23(9):1577-82. doi: 10.1097/IGC.0b013e3182a809e0.
9
Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy.腹腔内加压气溶胶化疗治疗腹膜癌病:疗效的初步证据。
Ann Surg Oncol. 2014 Feb;21(2):553-9. doi: 10.1245/s10434-013-3213-1. Epub 2013 Sep 5.
10
The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy.二线至六线治疗对初始紫杉烷/铂类为基础的化疗后复发卵巢癌患者生存的影响。
Ann Oncol. 2012 Oct;23(10):2605-2612. doi: 10.1093/annonc/mds203. Epub 2012 Aug 21.